Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. Co.'s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. We show 15 historical shares outstanding datapoints in our IMNM shares outstanding history coverage, used to compute IMNM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMNM market cap history over the course of time is important for investors
interested in comparing IMNM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMNM versus a peer is one thing; comparing
IMNM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMNM can fluctuate over the course of history.
With this page we aim to empower investors researching IMNM by allowing them to research the IMNM market cap history. |
Free IMNM Email Alerts:
Video: The Importance of Market Cap
